Therapy Areas: Diabetes
Eli Lilly launches Foundayo weight‑loss pill in the US
...
Lupin's Dapagliflozin Tablets receive US regulatory approval
8 April 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for it...
Caliway to present preclinical data on CBL-514 in combination with GLP-1R therapy at ADA 2026 Scientific Sessions
2 April 2026 - Caliway Biopharmaceuticals (TWSE:6919), a Taiwan-based clinical-stage biopharmaceutical company, announced on Thursday that the latest preclinical data on its first-in-class large-area ...
Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval
2 April 2026 - Pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Wednesday that the US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesit...
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
31 March 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Monday that its US partner Ollin Biosciences has reported final, 20-week study completion data from i...
Amgen reports Repatha (evolocumab) cuts risk of first major CV events by 31% in high-risk patients without known significant atherosclerosis
30 March 2026 - US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Saturday that Repatha (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering tr...